BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36951264)

  • 1. Nrf2 as a novel diagnostic biomarker for papillary thyroid carcinoma.
    Wang Z; Li J; Liu Z; Yue L
    Eur J Histochem; 2023 Mar; 67(2):. PubMed ID: 36951264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparity expression of gammaH2AX in papillary thyroid cancer and nodular goiter.
    Hu S; Zhang G; Xu J; Zhu X; Lu X; Jiang L; Wang Q; Hou X; Cao J; Ge M
    Clin Lab; 2014; 60(12):2031-7. PubMed ID: 25651738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
    Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS
    Head Neck; 2016 Apr; 38 Suppl 1():E1203-9. PubMed ID: 26268700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
    Ziros PG; Manolakou SD; Habeos IG; Lilis I; Chartoumpekis DV; Koika V; Soares P; Kyriazopoulou VE; Scopa CD; Papachristou DJ; Sykiotis GP
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1422-7. PubMed ID: 23766517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating BRAF
    Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
    BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
    Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prediction model incorporating the BRAF
    Liu S; Liu C; Zhao L; Wang K; Li S; Tian Y; Jiao B; Gui Z; Yu T; Zhang L
    Eur J Surg Oncol; 2021 Nov; 47(11):2774-2780. PubMed ID: 34483032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma.
    Qing W; Fang WY; Ye L; Shen LY; Zhang XF; Fei XC; Chen X; Wang WQ; Li XY; Xiao JC; Ning G
    Thyroid; 2012 Sep; 22(9):905-10. PubMed ID: 22870901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Expression of Erythrocyte Sedimentation Rate and C-reactive Protein in Papillary Thyroid Carcinoma and Nodular Goiter.
    Hou X; Jiang L; Chen C; Zhu X; Ge M
    Clin Lab; 2015; 61(7):793-9. PubMed ID: 26299079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
    Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
    Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
    Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
    JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting factors of central lymph node metastasis and BRAF
    Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF
    World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and significance of serum E-cadherin in patients with papillary thyroid carcinoma].
    Sun L; Wang DM; Zhang WJ; Zhang J; Wu JF
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jan; 31(2):123-126. PubMed ID: 29871201
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk and Prognostic Factors for BRAF
    Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
    Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.